Lonza announced the expansion of its peptides manufacturing capacities
03-May-2005
The investment is focused on several areas of Lonza's peptides and oligonucleotides (tides) large-scale cGMP manufacturing activities. To serve customers' demand for clinical trial material the construction of a new mid-scale tides plant is planned. Additional HPLC-purification and new lyophilization equipment as well as essential items of infrastructure will be installed.
Organizations
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically-Active Disease
Go to page
DOLD GmbH - Fellbach, Germany
Go to page
List_of_arctiid_genera:_T
Go to page
List_of_gelechiid_genera:_T
Go to page
Glide Pharma signs biologicals deal with major pharma company
Go to page
List_of_hesperiid_genera:V
Go to page
List_of_Apiaceae_genera
Go to page
Bethanechol
Go to page
Celsius® FFT|FFTp Bags | Deep-freeze containers | Sartorius
Go to page
Intercell AG appoints Staph Leavenworth Bakali as Chief Business Officer
Go to page
List_of_crambid_genera:_M
Go to page
FSP-Tech GmbH - Essen, Germany
Go to page